



Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
9 - 11 November 2010
CCV/CICG, Geneva

Tuesday, 9 November 2010

Time	Session	Purpose of session, target outcomes and questions for SAGE	
09:00	Welcome - introduction Dr Flavia Bustreo, Assistant Director-General, Family and Community Health, WHO Professor Helen Rees, Chair, SAGE		20mn
09:20	Report from IVB Director - Session 1 Presentation: J.-M. Okwo-Bele, WHO, 20mn Discussion: 40mn	FOR INFORMATION	1hr
10:20	Coffee/tea break	Break	20mn
10:40	Report from the GAVI Alliance secretariat - Session 2 Presentation: N. Schwalbe, GAVI Alliance, 20mn Discussion: 30mn	FOR INFORMATION	50mn
11:30	Regional priorities, major policy and implementation issues: reports from AMR, EUR and WPR - Session 3 AMR Presentation: C. Ruiz-Matus, WHO, 20mn Discussion: 20mn EUR Presentation: R. Martin, WHO, 20mn Discussion: 20mn	FOR INFORMATION AND DISCUSSION	2hrs
12:50	Lunch	Break	1hr

13:50	Regional priorities, major policy and implementation issues, (contd.) WPR Presentation: D. Sniadack, WHO, 20mn Discussion: 20mn		
14:30	Reports from other Advisory Committees in Immunization - Session 4 QUIVER report Presentation: A. Hinman, Chair of QUIVER, 10mn Discussion: 10mn GACVS report Presentation: P. Smith, Chair of GACVS, 10mn Discussion: 10mn IPAC report Presentation: S. Deeks, Chair of IPAC, 10mn Discussion: 10mn	FOR INFORMATION AND DISCUSSION	1hr 20mn
15:30	Coffee/tea break	Break	30mn
16:00	Reports from other Advisory Committees in Immunization, (contd.) ECBS report Presentation: E. Griffiths, Chair of ECBS, 10mn Discussion: 10mn		
16:20	Typhoid vaccines: feed-back on regional implementation of SAGE recommendations - Session 5 Introductory comments, N. Arora, SAGE, 5mn Typhoid vaccine use in countries - progress and challenges P. Namgyal, WHO, 15mn New initiatives for typhoid control - Typhoid Surveillance in sub-Saharan Project, M. Favorov, International Vaccine Institute, 10mn - Coalition against Typhoid, C. de Quadros, Sabin Vaccine Institute, 10mn Discussion: 50mn	FOR INFORMATION AND DISCUSSION Feedback on the progress, challenges and the opportunities for the use of typhoid vaccines in the control of typhoid in typhoid endemic countries Possibly providing further guidance on accelerating uptake of typhoid vaccines by typhoid endemic countries	1hr 30mn
17:50	Cocktail		

Wednesday, 10 November 2010

08:30	Seasonal influenza and H5N1 pandemic influenza vaccine - Session 6 H1N1 pandemic vaccine: update on pharmacovigilance and deployment, D. Wood, WHO, 10mn Discussion: 20mn Report from the SAGE working group on H5N1 vaccines, A. Reingold, member of the SAGE WG on H5N1 vaccines, 15mn Discussion: 30mn Report from the SAGE working group on influenza vaccines and immunization, L. Miller, Chair of SAGE WG on influenza vaccines and immunization, 15mn Discussion: 30mn	FOR INFORMATION, DISCUSSION, AND DECISION Provide revised recommendations on the use of H5N1 vaccines and on the WHO H5N1 stockpile Present SAGE with an update of the work of SAGE working group on influenza vaccines and immunization	2hrs
10:30	Coffee/tea break	Break	30mn
11:00	Polio eradication - Session 7 Major Programmatic Developments and Epidemiologic Impact, B. Aylward, WHO, 15mn Assessment of Current/Emerging Risks to Polio Eradication, B. Burkholder, CDC, 15mn Discussion: 30mn Report from the SAGE IPV Working Group, L. Miller, Chair of SAGE IPV WG, 10mn Discussion: 30mn	FOR DISCUSSION AND DECISION Report on SAGE recommendation to establish an independent monitoring and 'corrective action' process for the new Strategic Plan. Obtain SAGE perspectives on the impact to date of the Strategic Plan 2010-12 and the risks to completing polio eradication. For SAGE decision on (a) whether to extend the WG's timeline for its 2 nd deliverable (post-eradication polio immunization recommendations for low-income settings) to April 2012, and (b) expanding the mandate of the WG to include whether to continue immunizing against type 2 poliovirus in advance of type 1 & 3 eradication.	1hr 40mn
12:40	Lunch	Break	1hr
13:40	Feasibility of measles eradication - Session 8 Introduction of session, H. Bashour, SAGE, 10mn	FOR DECISION For decision on the recommendation of the ad hoc advisory group for the global technical consultation meeting to assess the feasibility of	2hrs 30mn

	<p>Summary of the findings and recommendations of the "Global technical consultation meeting to assess the feasibility of measles eradication", D. Durrheim, SAGE, 30mn</p> <p>Discussion: 1hr 50mn</p>	<p>measles eradication which include the following:</p> <ul style="list-style-type: none"> • Can and should measles be eradicated? • Is 2020 a feasible target for achieving measles eradication? • Should WHA consider establishing a target date for measles eradication once the South-East Asian Region has established an elimination target? <p>SAGE recommendations will then be presented to the WHA in May 2011</p>	
15:30	Coffee/tea break	Break	30mn
16:00	<p>Feasibility of measles eradication (contd.)</p> <p>Discussion: continued</p>		
16:40	<p>Immunization schedules: Update - Session 9</p> <p>Overview of the Optimizing Immunization Schedules process and how this has been applied to pneumococcal conjugate vaccines (PCV), P. Fine, London School of Hygiene and Tropical Medicine, 10mn</p> <p>Systematic review on alternative schedules for PCV, N. Low, Bern University, 15mn</p> <p>Using a mathematical model to assess the impact of alternative PCV schedules in the West African context, N. Gay, consultant, Hungerford, UK, 10mn</p> <p>What is the way forward? A.-M. Henao-Restrepo, WHO 10mn</p> <p>Discussion: 45mn</p>	<p>FOR INFORMATION AND DISCUSSION</p> <p>Using PCV as an example, the purpose of the session is to present the proposed process for optimizing immunization schedules at country level</p> <p>Advice by SAGE on:</p> <ul style="list-style-type: none"> • Whether or not the proposed approach to optimizing immunization schedules addresses SAGE's previous recommendations on the subject. • Whether or not the findings presented to the SAGE on PCV provide additional support to the need to continue to review the evidence for the immunization schedules for PCV and other vaccines in various epidemiological areas. • Priority vaccines to include in the review process and epidemiological scenarios to include in future assessments. 	1hr 30mn
18:10	End of meeting		

Thursday, 11 November 2010

08:30	<p>Low-middle-income countries: sustainable adoption and financing of new vaccines - Session 10</p> <p>Results of study on new vaccine adoption by lower-middle income countries, M. Makinen, Results for Development Institute and LMIC Study Director, 30mn</p> <p>Presentation of study recommendations, M. Makinen, 15mn</p> <p>Discussion: 30mn</p> <p>Presentation on role of WHO in implementation of study recommendations, M. Kaddar, Co-Chair, LMIC Advisory Group, WHO, 15mn</p> <p>Discussion: 30mn</p>	<p>FOR INFORMATION AND DISCUSSION</p> <p>Inform SAGE members on the factors impeding and opportunities facilitating the sustainable adoption and financing of new vaccines by LMICs</p> <p>Seek SAGE advice on the roles of WHO and (its) partners in implementing the study recommendations and on how to stimulate an enabling environment for middle-income countries to strengthen their immunization systems and introduce new vaccines</p> <ul style="list-style-type: none"> • What are the priority activities? • How can the LMIC strategy be defined and implemented as a collaborative initiative? • What will be the role of WHO in moving forward? 	2hrs
10:30	Coffee/tea break	Break	30mn
11:00	<p>Accessibility to affordable vaccines: gaps and WHO's role in supporting emerging vaccine manufacturers - Session 11</p> <p>Landscape Analysis of WHO's Role in Supporting Emerging Vaccine Manufacturers, J. Milstien, University of Maryland, 15mn</p> <p>Support to emerging vaccine manufacturers:</p> <ol style="list-style-type: none"> 1. The EPI manager's view of their needs and of the role of WHO, R. Hafiz, Ministry of Health, Pakistan, 10mn 2. Fostering partnerships for innovative vaccines <ul style="list-style-type: none"> Government initiative R. Guimarães (taped presentation), Secretary of Science, Technology and Strategic Goods, Brazil, 10mn International organization driven initiative, R. Carbis, International Vaccine Institute, Korea, (presentation delivered by Dr Rao Raman, Vice President, Shantha Biotechnics Ltd., India), 10mn 3. Impact on the market price, D. Atherly, PATH, 10mn 	<p>FOR DISCUSSION</p> <p>To present an overview of current WHO activities in support of the accessibility of affordable vaccines</p> <p>To specifically reflect on WHO models of support to emerging vaccine manufacturers</p> <p>To discuss and get directions on what the role of WHO should be in supporting emerging vaccine manufacturers in the context of other strategic activities and its comparative advantages and in view of the role of partner organizations</p>	2hrs 30mn

	Review of needs, current activities, gaps and proposed roles, H. Rees, SAGE, 5mn Discussion: 1hr		
13:00	Lunch	Break	1hr
14:00	Accessibility to affordable vaccines: WHO's role in supporting emerging vaccine manufacturers (contd.) Discussion: continued, 30mn		
14:30	Update on the epidemiology of the unimmunized and gender related issues - Session 12 Introduction, J. Hombach, WHO, 5mn Update on further analysis and plans to put into operation the findings of the review of the epidemiology of the unimmunized at local level, R. Eggers, WHO, 10mn Review of the DHS data on sex and immunization coverage and the determinants that impact on coverage, and a systematic review of the qualitative data on gender and immunization, X. Bosch-Capblanch & A. Martin Hilber, Swiss Tropical and Public Health Institute, 30mn Study on sex disaggregated data and their relevance to immunization, M. Widyono, PATH, 10mn Discussion: 35mn	FOR DISCUSSION Update SAGE on the workplan to put into operation the findings of the review of the epidemiology of the unimmunized at local level Guidance from SAGE on whether evidence supports the need to put priority on gender issues in immunization	1hr 30mn
16:00	Closing		30mn
16:30	End of meeting		